{"title":"What is in the bottle? An analysis of the ingredients in menopause supplements.","authors":"Poppy Sullivan, Anne-Marie Boylan, Joyce Catherine Harper","doi":"10.1080/13697137.2026.2719016","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Menopause supplements are a global market projected to reach $25 billion by 2030, despite a lack of evidence on their efficacy. This study analyzed the ingredients, doses and costs of menopause supplements in the UK.</p><p><strong>Method: </strong>A systematic search of nine UK retailers and Google Shopping was conducted using the terms 'menopause' and 'menopause supplements'. Products with the term 'menopause' in their name or description were included; duplicates, bundles and discontinued items were excluded. Ingredients were categorized as vitamins and minerals, botanicals, and other active and non-active ingredients. Doses and costs were recorded.</p><p><strong>Results: </strong>We identified 201 menopause supplements. Herbs (80.1%), vitamins (76.6%) and phytoestrogens (74.1%) were the most common ingredients. Vitamin B6 appeared in 69.2% of products, while zinc and magnesium were found in 48.8% and 47.3%, respectively. Red clover (38.8%) and sage (42.8%) were the most common phytoestrogen and herb. Costs ranged from £1.50 to £95 per month.</p><p><strong>Conclusion: </strong>Menopause supplements contain highly variable ingredients and are often expensive. They are being sold to women as a way to reduce menopause symptoms despite the limited empirical evidence currently available. Healthcare professionals should be aware of the wide variability in supplement formulations and discuss evidence-based treatment options with women considering these products.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-15"},"PeriodicalIF":3.9000,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2026.2719016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Menopause supplements are a global market projected to reach $25 billion by 2030, despite a lack of evidence on their efficacy. This study analyzed the ingredients, doses and costs of menopause supplements in the UK.
Method: A systematic search of nine UK retailers and Google Shopping was conducted using the terms 'menopause' and 'menopause supplements'. Products with the term 'menopause' in their name or description were included; duplicates, bundles and discontinued items were excluded. Ingredients were categorized as vitamins and minerals, botanicals, and other active and non-active ingredients. Doses and costs were recorded.
Results: We identified 201 menopause supplements. Herbs (80.1%), vitamins (76.6%) and phytoestrogens (74.1%) were the most common ingredients. Vitamin B6 appeared in 69.2% of products, while zinc and magnesium were found in 48.8% and 47.3%, respectively. Red clover (38.8%) and sage (42.8%) were the most common phytoestrogen and herb. Costs ranged from £1.50 to £95 per month.
Conclusion: Menopause supplements contain highly variable ingredients and are often expensive. They are being sold to women as a way to reduce menopause symptoms despite the limited empirical evidence currently available. Healthcare professionals should be aware of the wide variability in supplement formulations and discuss evidence-based treatment options with women considering these products.
期刊介绍:
Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women.
Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments.
The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.